ZNF423 depletion induces the integrated stress response and represents a potential vulnerability in NF1-associated MPNST
Preprint
Abstract
Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas with limited systemic therapies and represent the leading cause of mortality for individuals with neurofibromatosis type 1 (NF1). Malignant progression can reactivate developmental precursor programs that are largely absent from normal nerve and benign tumors, creating tumor-selective vulnerabilities. Zinc finger protein 423 (ZNF423; also known as OAZ/ROAZ) is a developmentally regulated transcription factor that delays olfactory precursor differentiation and has been implicated in B-cell malignancy. Here, we asked whether ZNF423 is reactivated and functionally required in NF1-associated MPNST. In genetically defined models, Nf1 loss reduced Zfp423 in a benign tumor cell-of-origin context, whereas combined Nf1 and Cdkn2a loss induced marked Zfp423 upregulation during transformation. ZNF423 depletion impaired DNA synthesis and proliferation, induced DNA damage signaling, and activated the integrated stress response (ISR), increasing sensitivity to cytotoxic agents. In an orthotopic MPNST model, shRNA-mediated suppression of ZNF423 reduced tumor initiation in vivo; however, tumors that eventually emerged showed restoration of ZNF423 expression. ZNF423 is developmentally restricted in the peripheral nerve lineage yet elevated in MPNST, with single-cell analyses of patient nerve sheath tumors revealing localized expression restricted to malignant cells rather than SOX10-positive benign tumor cells. These data identify ZNF423 as a putative malignant biomarker, a potential dependency in NF1-MPNST, and nominate downstream stress and genome maintenance pathways as cooperative therapeutic vulnerabilities. STATEMENT OF SIGNIFICANCE: ZNF423 is a developmentally restricted transcription factor selectively reactivated in NF1-associated malignant peripheral nerve sheath tumors. Targeted ablation triggers the integrated stress response, impairs DNA synthesis, sensitizes cells to chemotherapy and PARP inhibition, and restricts in vivo growth. ZNF423 represents a candidate biomarker and therapeutic vulnerability in this aggressive sarcoma.Keywords
Funding Information
- Riley Children's Foundation
- Ralph W. and Grace M. Showalter Research Trust
This publication has 70 references indexed in Scilit:
- Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumorCell Reports, 2022
- Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findingsHuman Mutation, 2018
- Transcriptional Addiction in CancerCell, 2017
- Cells of Origin in the Embryonic Nerve Roots for NF1-Associated Plexiform NeurofibromaCancer Cell, 2014
- Exome Capture Reveals ZNF423 and CEP164 Mutations, Linking Renal Ciliopathies to DNA Damage Response SignalingCell, 2012
- Zfp423 Expression Identifies Committed Preadipocytes and Localizes to Adipose Endothelial and Perivascular CellsCell Metabolism, 2012
- Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumorsGenes, Chromosomes and Cancer, 2011
- NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease OutcomeCell, 2010
- ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma OutcomeCancer Cell, 2009
- Poly(ADP-ribose) polymerase 1 interacts with OAZ and regulates BMP-target genesBiochemical and Biophysical Research Communications, 2003